OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Health Economics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Do renewable energy and health expenditures improve load capacity factor in the USA and Japan? A new approach to environmental issues	118
COVID-19 and income inequality in OECD countries	93
Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe	55
The COVID-19 crisis and telework: a research survey on experiences, expectations and hopes	54
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies	45
Comparison of ARIMA, ETS, NNAR, TBATS and hybrid models to forecast the second wave of COVID-19 hospitalizations in Italy	43
Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life	42
The economic burden of obesity in Italy: a cost-of-illness study	41
Health effects from heat waves in France: an economic evaluation	36
More room for telemedicine after COVID-19: lessons for primary care?	35
COVID-19 and the role of inequality in French regional departments	30
General population normative data for the EQ-5D-3L in the five largest European economies	28
Efficiency and productivity of health systems in prevention and control of non-communicable diseases in China, 2008–2015	28
Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states	26
The remarkably frequent use of EQ-5D in non-economic research	25
Effect of financial inclusion on out-of-pocket health expenditure: empirics from Ghana	23
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018	22
Is stronger religious faith associated with a greater willingness to take the COVID-19 vaccine? Evidence from Israel and Japan	22
Health state utility values by cancer stage: a systematic literature review	21
Does the universal medical insurance system reduce catastrophic health expenditure among middle-aged and elderly households in China? A longitudinal analysis	21
Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A	21
What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the dev	21
Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies	21
Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia	20
Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies	20

Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment	19
Comparison of the three-level and the five-level versions of the EQ-5D	19
Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China	18
Economic analysis of open versus laparoscopic versus robotic hepatectomy: a systematic review and meta-analysis	18
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE)	18
The impact of COVID-19 pandemic on insurance demand: the case of China	17
Economics of mental well-being: a prospective study estimating associated health care costs and sickness benefit transfers in Denmark	17
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression	17
The relationship between renewable energy use and health expenditures in EU countries	17
Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France	17
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations	16
The Italian NHS at regional level: same in theory, different in practice	16
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges	16
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions	16
The economic burden of amyotrophic lateral sclerosis: a systematic review	16
Reassessing the impact of health expenditure on income growth in the face of the global sanitary crisis: the case of developing countries	15
Can the Covid19 pandemic affect the achievement of the ‘Zero Hunger’ goal? Some preliminary reflections	15
Work ethics, stay-at-home measures and COVID-19 diffusion	15
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerl	15
Has the development of cancer biomarkers to guide treatment improved health outcomes?	15
The cost of lost productivity due to premature mortality associated with COVID-19: a Pan-European study	14
The effect of mental and physical health problems on sickness absence	14
Income and conversion handicaps: estimating the impact of child chronic illness/disability on family income and the extra cost of child chronic illness/child disability in Ireland using a standard of	14
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland	14
Income level and antibiotic misuse: a systematic review and dose–response meta-analysis	14
Does socioeconomic status affect hospital utilization and health outcomes of chronic disease patients?	14
COVID-19 health policy evaluation: integrating health and economic perspectives with a data envelopment analysis approach	14
Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis	13
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	13
The causal impact of sugar taxes on soft drink sales: evidence from France and Hungary	13
EQ-5D-5L Portuguese population norms	13
Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis	13
The impact of social health insurance on rural populations	13
Value drivers of development stage biopharma companies	13
Can drones save lives and money? An economic evaluation of airborne delivery of automated external defibrillators	13
Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia	12
The association between bed occupancy rates and hospital quality in the English National Health Service	12
Economic evidence with respect to cost-effectiveness of the transitional care model among geriatric patients discharged from hospital to home: a systematic review	12
Cost-effectiveness of the latent tuberculosis screening program for migrants in Stockholm Region	12
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain	12
Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting	12
Timing of non-pharmaceutical interventions to mitigate COVID-19 transmission and their effects on mobility: a cross-country analysis	12
The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies	11
Ageing and health care expenditures: the importance of age per se, steepening of the individual-level expenditure curve, and the role of morbidity	11
The residential healthcare for the elderly in Italy: some considerations for post-COVID-19 policies	11
The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?	11
The economics of alternative payment models for pharmaceuticals	11
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19	11
European union regulation of health technology assessment: what is required for it to succeed?	11
The impact of decentralisation on the performance of health care systems: a non-linear relationship	11

Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists	10
Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis	10
Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above	10
Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland	10
EQ-5D-5L: a value set for Romania	10
Economic and social cost of epilepsy in Poland: 5-year analysis	10
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	10
Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations	10
General practice in the EU: countries you see, customs you find	10
Mapping MacNew Heart Disease Quality of Life Questionnaire onto country-specific EQ-5D-5L utility scores: a comparison of traditional regression models with a machine learning technique	9
Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients	9
Can competition improve hospital quality of care? A difference-in-differences approach to evaluate the effect of increasing quality transparency on hospital quality	9
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction	9
Voluntary private health insurance, health-related behaviours and health outcomes: evidence from Russia	9
Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China	9
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic	9
Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups	9
Willingness to provide informal care to older adults in Germany: a discrete choice experiment	9
Business cycle and mortality in Spain	9
Population norms in France with EQ-5D-5L: health states, value indexes, and VAS	9
Willingness-to-pay for cancer treatment and outcome: a systematic review	9
Consideration of quality of life in the health technology assessments of rare disease treatments	9
The cost-effectiveness of unilateral cochlear implants in UK adults	8
Population preferences for non-pharmaceutical interventions to control the SARS-CoV-2 pandemic: trade-offs among public health, individual rights, and economics	8
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease	8
The impact of nurse staffing levels on nursing-sensitive patient outcomes: a multilevel regression approach	8
The effects of patient cost-sharing on health expenditure and health among older people: Heterogeneity across income groups	8
Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study	8
Complexities of health and acceptance of electronic health records for the Austrian elderly population	8
Does voluntary health insurance improve health and longevity? Evidence from European OECD countries	8
The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria: a time trade-off and discrete choice experiment study	8
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries	8
Communities and testing for COVID-19	8
Costs and management of patients with hemophilia A in France: the Hemraude study	8
Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation	7
Effects of establishing a financing scheme for outpatient care on inpatient services: empirical evidence from a quasi-experiment in China	7
The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups	7
Canada population norms for the EQ-5D-5L	7
Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology	7
Social costs of obesity in the Czech Republic	7
Developing an Australian utility value set for the Early Childhood Oral Health Impact Scale-4D (ECOHIS-4D) using a discrete choice experiment	7
Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment	7
Financial risk allocation and provider incentives in hospital–insurer contracts in The Netherlands	7
The impact of inpatient bed capacity on length of stay	7
The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study	7
The goal of risk equalization in regulated competitive health insurance markets	7
Inequality, public health, and COVID-19: an analysis of the Spanish case by municipalities	7
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study	7
Regional medical practice variation in high-cost healthcare services	7
Production losses due to mortality associated with modifiable health risk factors in Poland	7